A phase I/II clinical trial is currently evaluating the combination of the IDO inhibitor epacadostat with the anti-PD-1 antibody pembrolizumab in various solid tumors, including RCC, with promising results previously reported in melanoma (166–168). This evidence concerns the gene IDO1 and renal cell carcinoma.